ArticleBreast cancer research and treatment2021

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.

Emma J Groen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.